GlobeNewswire by notified

New data reveal that 4 out of 5 breast cancer patients eligible for genomic testing are not told it is available to them

Share

Surprising statistics emerge from a European survey led by Cancer Patients Europe as part of its my Cancer my Concern (myC) initiative

Brussels, Nov. 21, 2022 (GLOBE NEWSWIRE) -- If you were diagnosed with cancer, you would hope you were being given the chance to benefit from the latest advances in the field of oncology. However, initial data from a recent patient survey conducted in five European countries by Cancer Patients Europe (CPE), with the support of Exact Sciences, demonstrate that the majority of breast cancer patients eligible for genomic testing did not even know that it was an option for them.

Genomic testing allows eligible patients with early-stage breast cancer the opportunity to benefit from personalised or precision medicine. Used as a therapy aid by physicians to tailor treatment plans to their patients’ individual cancers, genomic testing can help in some treatment decisions, including whether patients are likely to benefit from adjuvant chemotherapy. Therefore, it can spare many women with early-stage breast cancer from chemotherapy and the associated side effects. Despite the importance and growing utility of personalised medicine, the survey demonstrated that 59% of overall respondents had never heard about it. 

“The data show there is an urgent need to raise awareness and understanding of the value of genomic testing in breast cancer across Europe, amongst medical professionals, patients, policy makers and payers,” states Dr Fatima Cardoso, member of the myC Survey Advisory Committee and Director of the Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal. “Genomic testing has proven its value with high evidence, and it is also cost-effective. However, it is not reimbursed nor easily available in many European countries.”

In addition, the survey data highlight the need for more information to be available to patients throughout their cancer diagnosis and treatment, especially from medical professionals whom they quoted as their preferred source of information. Specifically, respondents said they would have liked to receive more information on their type of cancer, additional testing, treatment options and long-term treatment effects.

“The results of the survey bring to light some shocking truths in the treatment and management of cancer patients across Europe,” said Conchi Biurrun, Board Secretary, CPE. “Cancer Patients Europe is dedicated to accelerating discussions with policymakers and other key stakeholders to raise awareness of genomic testing and ensure its implementation into routine clinical practice to help determine whether patients should undergo chemotherapy.” 

Dr Steven Bellamy, Chief Medical Officer, International, Exact Sciences, said, “we are delighted to support CPE’s myC initiative, a programme that is proving critical in our understanding of cancer care across Europe. As the data point to a significant gap in the knowledge of genomic testing, this collaboration supports an important shared goal: helping patients, and we are honoured to be a part of it”.

About the myC Patient Survey in Genomics and Breast Cancer

  • The 42-question survey was completed by a total of 1,383 respondents across five countries (France, Germany, Italy, Spain, UK) over a six-week period in September/October 2022. 
  • Eighty-three percent (83%) of respondents were breast cancer patients, 50% of whom were eligible for genomic testing.
  • Eighty-four percent (84%) of eligible patients stated they did not have enough information to make a decision on whether to take a genomic test.
  • Only a quarter (25%) of eligible patients took a genomic test.

About Cancer Patients Europe (CPE)

Cancer Patients Europe is a recently established pan-European, pan-cancer association. The association’s mission is to provide a balanced representation of cancer patients and their experiences across Europe, bridging the gap between European and national practice implementation and reducing the burden of cancer on patients and survivors, their caregivers, healthcare systems, and society as a whole.

About the my Cancer my Concern (myC) Initiative

myC is a CPE initiative which aims to raise awareness of the benefits and values of genomic testing in cancer. Personalised treatment decisions are key to this effort and genomic testing is an example of current progress in this area. The project is part of CPE’s broader goal to improve the management of cancer for patients across Europe and call European policymakers to action.

The myC initiative is supported by Exact Sciences, a cancer diagnostics company.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fluence Responds to Misleading Short Seller Report22.2.2024 23:32:54 CET | Press release

ARLINGTON, Va., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (“Fluence” or “the Company”) (NASDAQ: FLNC), a leading global provider of energy storage products, services, and optimization software for renewables and storage, today issued a statement in response to a report published by a known short-seller. The Company believes that the report is an attempt by a self-interested short-seller to profit at the expense of Fluence’s shareholders by manipulating Fluence’s stock price. We believe that the report contains numerous inaccuracies and distortions. The Company believes it is important to set the record straight regarding three blatant misrepresentations: The short-seller's report references pending litigation between Fluence and Siemens Energy, attempting to characterize it as a "critical and dramatic development." While any dispute with a customer is unfortunate, this is a small, ordinary course commercial dispute arising from a single project. Fluence brought the action

Galapagos announces full year 2023 results and outlook for 202422.2.2024 22:01:00 CET | Press release

Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December 2023Operational cash burni of €414.8 million, within guidance 2023 and year-to-date key updates: Transferred Jyseleca® business, including approximately 400 positions, to Alfasigma S.p.A.Achieved encouraging data from ongoing Phase 1/2 studies with CD19 CAR-T product candidates, GLPG5101 in rrNHL and GLPG5201, in rrCLL, with or without RTExpanded CAR-T pipeline with start of Phase 1/2 study with BCMA CAR-T product candidate GLPG5301 in rrMMEnrolled first patients in Phase 2 study with TYK2 inhibitor, GLPG3667, in DM and SLEFor strategic reasons, it was decided not to continue development of CD19 CAR-T candidate in rSLEExpanded point-of-care CAR-T network in the U.S. with manufacturing agreements with Landmark Bio and Thermo Fisher Scientific Signed strategic research and license collaboration with Brid

Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors22.2.2024 19:02:45 CET | Press release

Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors Paris, February 22, 2024. At its meeting on February 22, 2024, Sanofi’s Board of Directors has decided to propose, on the occasion of its next General Shareholder Meeting to be held on April 30, 2024, the renewal of the terms of office of Rachel Duan and Lise Kingo and the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors. Diane Souza, Member of the Audit and Compensation Committees, and Thomas Südhof, Chairman of the Scientific Committee, will leave the Board of Directors at the end of their second terms. The Chairman warmly thanked them for their valued contribution to the Board of Directors and the specialized committees to which they belonged during their terms in office. The Chairman specified that, in order to prepare as effectively as possible for the end, in 2025, of the term of office as director of F

EVS reports 2023 results22.2.2024 18:30:00 CET | Press release

Publication on February 22, 2024, after market closing Regulated and inside information – Press release annual results EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports 2023 results Liège, Belgium, February 22nd, 2024 EVS further delivers profitable growth in 2023, validating the effectiveness of its PlayForward strategy The robust financial performance of EVS in 2023 underscores the effectiveness of the implemented strategy aimed at fostering sustained and profitable long-term growth. Despite the absence of significant Big Event Rental revenue in an uneven year 2023, EVS achieved record-breaking revenue and demonstrated strong profitability. This success serves as a testament to the efficacy of its PlayForward strategy. Full-year Highlights Order intake outpacing revenue at EUR 192.9 million, including EUR 7.4 million of Big Event Rental (BER).Revenue performance landing north of our guidance at EUR 173.2 million, growing 16.9%

RevoluGROUP Canada Inc. Issues Incentive Share Options22.2.2024 18:23:23 CET | Press release

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the "Company") announces that incentive share options to purchase up to 5,200,000 common shares of the Company were granted to consultants and Directors of the Company, with an exercise price of $0.05 per share. The incentive share options have been granted pursuant to the Company's 10% rolling stock option plan and will expire twenty-four months from the grant date. Should all announced options be exercised in the term, the aggregate amount payable to the treasury would be CA $ 260,000. The options are to be granted as shown below: Francisco Moreno Balboa1,500,000Gavin McMillan500,000Bernard Lonis500,000Alfredo Manresa Ruiz500,000Fernando Guillen Hernandez500,000 An additional 1,700,000 options were also granted to consultants in the Company who have provided valuable assistance in the development of products, business development, solution integra

HiddenA line styled icon from Orion Icon Library.Eye